Hope to resolve this soon: SII CEO on EU travel issues

Hope to resolve this soon: SII CEO Adar Poonawalla on Indians facing travel issues due to Covishield

SII CEO Adar Poonawalla assured that he was taking steps to resolve the issue.

Serum Institute of India CEO Adar Poonawalla. Credit: Reuters Photo

Covishield, the AstraZeneca-Oxford vaccine manufactured in India, not being eligible for the European Union’s “Green Pass”, the Pune-based Serum Institute of India (SII) has raised the issue at diplomatic levels.

SII CEO Adar Poonawalla assured that he was taking steps to resolve the issue.

“I realise that a lot of Indians who have taken Covishield are facing issues with travel to the EU, I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries,” Poonawalla tweeted on Monday.

Read: Most Covid-19 patients in Delhi hospitals are critical

Currently, only four vaccines have been approved by the European Medicines Agency (EMA) which can be used by the EU member states to issue the certificates. The four vaccines are Comirnaty of Pfizer/BioNTech, Moderna and Vaxzervria by AstraZeneca-Oxford and Johnson & Johnson's Janssen.

In India, people have been administered Covishield or Covaxin and a few of them received Sputnik V.

Get a round-up of the day's top stories in your inbox

Check out all newsletters

Get a round-up of the day's top stories in your inbox